Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 5 for:    ARDF 26 OR GLIQUIDONE OR GLURENORM

Incretin-based Drugs and the Risk of Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02456428
Recruitment Status : Completed
First Posted : May 28, 2015
Last Update Posted : April 19, 2016
Sponsor:
Collaborators:
Drug Safety and Effectiveness Network, Canada
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Canadian Network for Observational Drug Effect Studies, CNODES

Brief Summary:

The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure (HF) compared to other combinations of oral hypoglycemic agents (OHA).

The investigators will carry out separate population based cohort studies using administrative health databases in six jurisdictions in Canada, the US and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for HF. Analyses will be done separately for groups of patients with and without prior HF. The results from the separate sites will be combined to provide an overall assessment of the risk of HF in users of incretin-based drugs and by class of incretin-based drugs.


Condition or disease Intervention/treatment
Type 2 Diabetes Mellitus Drug: DPP-4 inhibitors Drug: GLP-1 analogs Drug: Insulins Drug: Biguanides Drug: Sulfonylureas Drug: Thiazolidinediones Drug: Alpha-glucosidase inhibitors Drug: Meglitinides

  Show Detailed Description

Layout table for study information
Study Type : Observational
Actual Enrollment : 1499650 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Incretin-based Drugs and the Risk of Heart Failure: A Multi-center Network Observational Study
Study Start Date : March 2014
Actual Primary Completion Date : May 2015
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Group/Cohort Intervention/treatment
Treated with incretins
Current use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) alone or in combination with other anti-diabetic drugs (if the prescription overlaps with the index or event day with a 30-day grace period).
Drug: DPP-4 inhibitors
Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • incretin-based drugs
  • sitagliptin
  • vildagliptin
  • saxagliptin

Drug: GLP-1 analogs
Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • incretin-based drugs
  • exenatide
  • liraglutide

Treated with insulin
Current use of insulins between base cohort entry and the index or event day (alone or in combination with other anti-diabetic drugs) and no current use of incretin-based drugs.
Drug: Insulins
Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
Other Names:
  • insulins and analogues for injection, fast-acting
  • insulins and analogues for injection, intermediate-acting
  • insulins and analogues for injection, long-acting
  • insulins and analogues for inhalation

Treated with ≥2 oral hypoglycemic agents
Current use of 2 or more non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescriptions overlap with the index or event day with a 30-day grace period), and no current use of incretin-based drugs or insulins.
Drug: Biguanides
Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • phenformin
  • metformin
  • buformin

Drug: Sulfonylureas
Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • glibenclamide
  • chlorpropamide
  • tolbutamide
  • glibornuride
  • tolazamide
  • carbutamide
  • glipizide
  • gliquidone
  • gliclazide
  • metahexamide
  • glisoxepide
  • glimepiride
  • acetohexamide
  • glymidine

Drug: Thiazolidinediones
Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • troglitazone
  • rosiglitazone
  • pioglitazone

Drug: Alpha-glucosidase inhibitors
Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • acarbose
  • miglitol
  • voglibose

Drug: Meglitinides
Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event)day.
Other Names:
  • oral hypoglycemic agent
  • repaglinide
  • nateglinide

Treated with single oral agent
Current use of any single non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescription overlaps with the index or event day with a 30-day grace period) and no current use of more than 2 OHAs, incretin-based drugs, or insulins.
Drug: Biguanides
Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • phenformin
  • metformin
  • buformin

Drug: Sulfonylureas
Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • glibenclamide
  • chlorpropamide
  • tolbutamide
  • glibornuride
  • tolazamide
  • carbutamide
  • glipizide
  • gliquidone
  • gliclazide
  • metahexamide
  • glisoxepide
  • glimepiride
  • acetohexamide
  • glymidine

Drug: Thiazolidinediones
Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • troglitazone
  • rosiglitazone
  • pioglitazone

Drug: Alpha-glucosidase inhibitors
Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • acarbose
  • miglitol
  • voglibose

Drug: Meglitinides
Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event)day.
Other Names:
  • oral hypoglycemic agent
  • repaglinide
  • nateglinide

Not currently exposed group
All patients not currently exposed to: incretin-based drugs, insulins, ≥2 OHAs, or a single OHA.



Primary Outcome Measures :
  1. Hospitalization for incident heart failure [ Time Frame: Patients were followed from the date of study cohort entry until hospitalization for incident heart failure, censoring, or for up to 87 months. ]

    Patients hospitalized for incident heart failure (HF) recorded in either the discharge abstract or hospitalization record with the following ICD codes:

    ICD-9 code: 428.x

    ICD-10 code: I50.x

    For patients who had no history of prior HF, cases were identified by the presence of a HF diagnosis in any position (most responsible, primary, or secondary), while for patients with a history of established HF, the event definition was restricted to those with a HF diagnosis as the primary or most responsible reason for hospitalization.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
In each jurisdiction, a base cohort will be assembled including all patients with a first-ever prescription for a non-insulin anti-diabetic drug. Base cohort entry is defined as the date of prescription or dispensation of a first-ever non-insulin anti-diabetic drug. From this base cohort, a study cohort will be formed consisting of all patients who initiated a new anti-diabetic drug class during the year in which incretin-based drugs entered the market in each jurisdiction or any time thereafter. Study cohort entry is defined by the prescription date of the newly-prescribed drug class. Two separate cohorts will be created based on the presence or absence of a history of HF prior to and including study cohort entry.
Criteria

Inclusion Criteria:

  • Patients with a first-ever prescription for a non-insulin anti-diabetic drug, including biguanides, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 analogs, alpha-glucosidase inhibitors, meglitinides, or combinations of these drugs from the earliest availability of data at each site to the last date of availability of data.
  • Patients with at least 1 year of history in the database.
  • Patients at least 18 years of age.

Exclusion Criteria:

  • Patients who died or left the cohort before the year the first incretin-based drug entered the market.
  • Patients who never added-on or switched to a new anti-diabetic drug after incretin-based drugs entered the market up until June 30, 2014.
  • Patients diagnosed with HIV or initiating HAART therapy before and at study cohort entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02456428


Locations
Layout table for location information
Canada, Quebec
Lady Davis Institute for Medical Research, Jewish General Hospital
Montreal, Quebec, Canada, H3T1E2
Sponsors and Collaborators
Canadian Network for Observational Drug Effect Studies, CNODES
Drug Safety and Effectiveness Network, Canada
Canadian Institutes of Health Research (CIHR)
Investigators
Layout table for investigator information
Principal Investigator: Pierre Ernst, MD, MSc Lady Davis Institute for Medical Research, Jewish General Hospital - McGill University

Publications of Results:
Layout table for additonal information
Responsible Party: Canadian Network for Observational Drug Effect Studies, CNODES
ClinicalTrials.gov Identifier: NCT02456428     History of Changes
Other Study ID Numbers: Q13-06C
First Posted: May 28, 2015    Key Record Dates
Last Update Posted: April 19, 2016
Last Verified: April 2016

Keywords provided by Canadian Network for Observational Drug Effect Studies, CNODES:
Incretins
Antidiabetic Agents
Heart Failure

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Heart Failure
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Heart Diseases
Cardiovascular Diseases
Insulin
Insulin, Globin Zinc
Sitagliptin Phosphate
Pioglitazone
Liraglutide
Exenatide
Saxagliptin
Rosiglitazone
Vildagliptin
2,4-thiazolidinedione
Biguanides
Meglitinide
Troglitazone
Acetohexamide
Hypoglycemic Agents
Incretins
Dipeptidyl-Peptidase IV Inhibitors
Glycoside Hydrolase Inhibitors
Physiological Effects of Drugs
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Protease Inhibitors